SH2D3C

Across TCGA pan-cancer cohorts, SH2D3C mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SH2D3C data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SH2D3C mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SH2D3C expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where SH2D3C mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.985	0.144	.008	10	view →
PDAC	OS	Median	IV	0.293	0.943	.038	3	view →
LUAD	DFS	Quartile	All	1.000	0.512	.028	2	view →
HNSC	OS	Quartile	All	0.956	0.766	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SH2D3C–CCRCC (DFS)

Open the CCRCC breakdown →